Neurogene Stock Technical Analysis
| NGNE Stock | 18.31 0.68 3.58% |
As of the 26th of January, Neurogene secures the Risk Adjusted Performance of (0.09), standard deviation of 5.13, and Mean Deviation of 3.91. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurogene, as well as the relationship between them. Please verify Neurogene market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Neurogene is priced some-what accurately, providing market reflects its recent price of 18.31 per share. Given that Neurogene has information ratio of (0.15), we recommend you to check Neurogene's last-minute market performance to make sure the company can sustain itself at a future point.
Neurogene Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Neurogene, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to NeurogeneNeurogene | Build AI portfolio with Neurogene Stock |
Neurogene Analyst Consensus
| Target Price | Advice | # of Analysts | |
| 59.0 | Strong Buy | 7 | Odds |
Most Neurogene analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Neurogene stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Neurogene, talking to its executives and customers, or listening to Neurogene conference calls.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neurogene 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neurogene's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neurogene.
| 10/28/2025 |
| 01/26/2026 |
If you would invest 0.00 in Neurogene on October 28, 2025 and sell it all today you would earn a total of 0.00 from holding Neurogene or generate 0.0% return on investment in Neurogene over 90 days. Neurogene is related to or competes with Lineage Cell, Ocugen, Fulcrum Therapeutics, Autolus Therapeutics, ADC Therapeutics, Benitec Biopharma, and Solid Biosciences. Neurogene is entity of United States. It is traded as Stock on NASDAQ exchange. More
Neurogene Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neurogene's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neurogene upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 23.85 | |||
| Value At Risk | (9.34) | |||
| Potential Upside | 7.26 |
Neurogene Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurogene's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neurogene's standard deviation. In reality, there are many statistical measures that can use Neurogene historical prices to predict the future Neurogene's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.21) | |||
| Treynor Ratio | (0.31) |
Neurogene January 26, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 3.91 | |||
| Coefficient Of Variation | (715.86) | |||
| Standard Deviation | 5.13 | |||
| Variance | 26.35 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.21) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 23.85 | |||
| Value At Risk | (9.34) | |||
| Potential Upside | 7.26 | |||
| Skewness | (0.32) | |||
| Kurtosis | 0.7939 |
Neurogene Backtested Returns
Neurogene has Sharpe Ratio of -0.14, which conveys that the firm had a -0.14 % return per unit of risk over the last 3 months. Neurogene exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neurogene's Standard Deviation of 5.13, risk adjusted performance of (0.09), and Mean Deviation of 3.91 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 2.31, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neurogene will likely underperform. At this point, Neurogene has a negative expected return of -0.73%. Please make sure to verify Neurogene's accumulation distribution, as well as the relationship between the day typical price and relative strength index , to decide if Neurogene performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.74 |
Good predictability
Neurogene has good predictability. Overlapping area represents the amount of predictability between Neurogene time series from 28th of October 2025 to 12th of December 2025 and 12th of December 2025 to 26th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neurogene price movement. The serial correlation of 0.74 indicates that around 74.0% of current Neurogene price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.74 | |
| Spearman Rank Test | 0.73 | |
| Residual Average | 0.0 | |
| Price Variance | 1.54 |
Neurogene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Neurogene Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Neurogene volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Neurogene Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Neurogene on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Neurogene based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Neurogene price pattern first instead of the macroeconomic environment surrounding Neurogene. By analyzing Neurogene's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Neurogene's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Neurogene specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2025 | 2026 (projected) | Payables Turnover | 2.19 | 1.54 | Days Of Inventory On Hand | 14.87 | 13.22 |
Neurogene January 26, 2026 Technical Indicators
Most technical analysis of Neurogene help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Neurogene from various momentum indicators to cycle indicators. When you analyze Neurogene charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 3.91 | |||
| Coefficient Of Variation | (715.86) | |||
| Standard Deviation | 5.13 | |||
| Variance | 26.35 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.21) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 23.85 | |||
| Value At Risk | (9.34) | |||
| Potential Upside | 7.26 | |||
| Skewness | (0.32) | |||
| Kurtosis | 0.7939 |
Neurogene January 26, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Neurogene stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.06 | ||
| Daily Balance Of Power | (0.62) | ||
| Rate Of Daily Change | 0.96 | ||
| Day Median Price | 18.67 | ||
| Day Typical Price | 18.55 | ||
| Price Action Indicator | (0.70) | ||
| Market Facilitation Index | 1.09 |
Complementary Tools for Neurogene Stock analysis
When running Neurogene's price analysis, check to measure Neurogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurogene is operating at the current time. Most of Neurogene's value examination focuses on studying past and present price action to predict the probability of Neurogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurogene's price. Additionally, you may evaluate how the addition of Neurogene to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |